Pavella - Undiscovered Biotechnology Stock
Summary Pavella Therapeutics (PVLA) has shown significant price appreciation, gaining 90% since a Trend Seeker buy signal on 2/5, and 105.81% over the last year. The company focuses on developing therapies for rare genetic skin diseases, with its lead product QTORIN rapamycin in advanced clinical trials. Technical indicators are strong...